Human Insulin Market

Human Insulin Market Overview 2024-2032:

The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The growing incidences of diabetes, rising geriatric population, rapid advancements in human insulin production, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

Human insulin refers to a peptide hormone that serves as a vital regulator of glucose metabolism within the human body. It is produced by pancreatic beta cells and plays a fundamental role in maintaining normal blood sugar levels. Human insulin is available in various forms, including short-acting, intermediate-acting, and long-acting formulations. It is widely used for the management of type 1 diabetes, diabetic ketoacidosis (DKA), gestational diabetes, and type 2 diabetes. It aids in achieving optimal blood glucose control and minimizing the risk of long-term complications associated with the disease. Human insulin also offers enhanced safety and efficacy profile, as it closely mimics the body's natural insulin production.

The implementation of supportive government policies to increase awareness regarding diabetes treatment and provide access to high-quality healthcare facilities is contributing to the market growth. Furthermore, the shifting trends towards personalized medicine and precision therapies are facilitating product demand as it allows dosage adjustments and customized insulin regimens, which improves patient outcomes. Besides this, aggressive marketing and promotional activities by manufacturers to improve brand visibility, increase awareness, and attract new customers are propelling the market growth. Moreover, the growing awareness and education among the masses regarding the importance of human insulin is supporting the market growth. Other factors, including the rapid expansion of the healthcare infrastructure, increasing investment in developing advanced production methods, and growing partnerships between key players, are anticipated to drive the market growth.

Human Insulin Market Trends/Drivers:

The growing incidences of diabetes

Human insulin plays a vital role in the treatment and management of diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels. It is widely used in insulin replacement, individualized therapy, and the management of specific conditions. Furthermore, the widespread product utilization in type 1 diabetes treatment to provide necessary insulin that bodies cannot produce, thus aiding in regulating blood sugar levels and preventing hyperglycemia, is supporting the market growth. Additionally, it is taken as an oral medication to supplement the body's insulin supply and improve glucose utilization. Apart from this, the rising product adoption in insulin pump therapy to deliver a continuous supply of insulin throughout the day, mimicking the basal insulin secretion of a healthy pancreas, is contributing to the market growth. Moreover, human insulin plays a critical role in preoperative and critical care settings to prevent glucose fluctuations and reduce the risks of surgical complications.

The rising geriatric population

Human insulin plays a crucial role in achieving optimal glycemic control in the geriatric population suffering from diabetes. It allows for individualized therapy and precise dosage adjustments to meet the specific needs of aging individuals based on factors such as age, medical history, renal function, and overall health status. Furthermore, human insulin has a well-established safety profile and has been used for decades in the treatment of diabetes, making it less risky for the geriatric population compared to newer treatments. Additionally, it aids in minimizing the risk of hypoglycemia in the elderly population compared to certain other diabetes medications. Apart from this, human insulin can be administered through various methods, including insulin pens, syringes, and insulin pumps, which allows healthcare providers to choose the most appropriate insulin delivery method based on the needs and preferences of geriatric individuals.

Rapid advancements in human insulin production

The introduction of recombinant deoxyribonucleic acid (DNA) technology, which eliminates the need for animal-based insulin extraction and provides a more consistent and reliable source of insulin, is positively influencing the market growth. Furthermore, the utilization of a continuous manufacturing process, which improves efficiency and productivity by allowing continuous and uninterrupted production of insulin, reducing time, saving cost, and enabling rapid response to changes in demand, is contributing to the market growth. Additionally, the recent advancements in bioprocessing techniques, such as the optimization of fermentation conditions, media formulation, and cell culture processes, which aid in reducing production costs while maintaining high product quality, are supporting the market growth. Moreover, the integration of advanced processing techniques, such as chromatography, filtration, and affinity-based separations, to improve the efficiency and effectiveness of insulin purification is strengthening the market growth.

Human Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human insulin market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, distribution channel, and disease type.

Breakup by Product Type:

• Drugs
  • Human Insulin Analogs and Biosimilars
    • Rapid Acting
    • Long Acting
    • Premixed
  • Human Insulin Biologics
    • Short Acting
    • Intermediate Acting
    • Premixed
• Delivery Devices
  • Pens
    • Reusable Pens
    • Disposable Pens
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Syringes
  • Others
     

Drugs dominate the market

The report has provided a detailed breakup and analysis of the market based on the product type. This includes drugs (human insulin analogs and biosimilars (rapid acting, long acting, and premixed) and human insulin biologics (short acting, intermediate acting, and premixed)) and delivery devices (pens (reusable pens and disposable pens), pen needles (standard pen needles and safety pen needles), syringes, and others). According to the report, drugs represented the largest market segment.

Drugs are dominating the market growth as they have been extensively researched and proven to be effective in managing diabetes. Furthermore, their established market presence has created familiarity and confidence among prescribers, leading to their continued dominance. Apart from this, human insulin drugs are generally more accessible and affordable compared to newer, patented insulin alternatives. Their easy accessibility and affordability have contributed to the widespread use of these drugs, particularly in resource-limited settings. Besides this, they have received regulatory approvals from health authorities around the world, which ensure that human insulin drugs meet quality standards and efficacy requirements. Moreover, human insulin drugs have been widely accepted by patients with diabetes due to their long history of use and proven effectiveness.

Breakup by Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Retail Stores
• Others
   

Retail Pharmacies dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, online retail stores, and others. According to the report, the distribution channel represented the largest market segment.

Retail pharmacies are situated in easily accessible locations, such as shopping centers, neighborhoods, and urban areas, which makes it convenient for patients with diabetes to access their prescribed medications. Furthermore, they have an extensive network of stores with multiple locations across cities, regions, and countries, which ensures that patients can find a nearby retail pharmacy to fill their human insulin prescriptions, irrespective of their location. Additionally, retail pharmacies have established relationships with various insurance providers and government healthcare programs, allowing for smooth reimbursement processes. Moreover, they provide additional services beyond prescription dispensing, including the proper use of human insulin, injection techniques, blood glucose monitoring, and lifestyle modifications.

Breakup by Disease Type:

• Type I Diabetes
• Type II Diabetes
   

Type I diabetes holds the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes type I and type II diabetes. According to the report, type I diabetes represented the largest market segment.

Type 1 diabetes holds the majority market share owing to its widespread prevalence across the globe. Furthermore, individuals with type 1 diabetes require insulin from the time of diagnosis throughout their lives. This substantial need for human insulin necessitates its steady supply to meet the rising demand for insulin replacement therapy. Furthermore, the absence of natural insulin production in type 1 diabetes creates a significant market demand as the primary source of insulin replacement. Along with this, human insulin provides a closer match to the insulin needs of individuals with type 1 diabetes compared to other insulin analogs, as it is structurally identical to the insulin naturally produced in the human body.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America exhibits a clear dominance in the market, accounting for the largest human insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the market as it has a significant burden of diabetes, with both type 1 and type 2 diabetes being prevalent in the region. Furthermore, it boasts a well-developed healthcare infrastructure characterized by advanced medical facilities, research institutions, and pharmaceutical companies, which supports the production, distribution, and accessibility of human insulin. Additionally, North America is at the forefront of technological advancements in the healthcare sector, including the development of innovative insulin delivery systems, such as insulin pens and insulin pumps, which enhance the administration and effectiveness of human insulin. Moreover, the presence of several leading pharmaceutical companies that are actively engaged in the production and distribution of human insulin is acting as another growth-inducing factor. Apart from this, North America has well-established regulatory bodies which ensure the safety, efficacy, and quality of pharmaceutical products, including human insulin.

Competitive Landscape:

The leading companies in the market are investing in research and development (R&D) projects to create innovative human insulin products. They are focusing on improving the pharmacokinetics, delivery systems, and formulations of insulin to enhance patient convenience and adherence. Apart from this, companies are expanding their presence in emerging markets due to the growing diabetic population and increasing healthcare access. Additionally, they are establishing partnerships with local distributors, healthcare providers, and regulatory authorities to navigate the regulatory landscape and ensure the availability of their human insulin products. Moreover, several key players are developing a range of insulin formulations with varying durations of action, which allows them to capture a broader market share and meet the specific requirements of patients with different types of diabetes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• B. Braun Melsungen AG
• Becton, Dickinson and Company (BD)
• Biocon
• Eli Lilly and Company
• Gulf Pharmaceutical Industries (Julphar)
• Novo Nordisk A/S
• Pfizer Inc.
• Groupe Sanofi
• SEDICO Co.
• Wockhardt Limited
• Ypsomed AG

Recent Developments:

• In December 2021, Dickinson and Company (BD) announced that "embecta" will be the name of the publicly-traded company that will hold BD's Diabetes Care business.
• In November 2022, Biocon Sdn. Bhd., a subsidiary of Biocon in Malaysia, announced that it had been awarded a three-year contract for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.
• In February 2023, Eli Lilly and Company announced a partnership with International Agencies (Bangladesh) Ltd. (IABL) to ensure access to high-quality, affordable insulin in Bangladesh.

Human insulin Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the human insulin market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global human insulin market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the human insulin industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.